Abstract
Apathy is an increasingly recognized concomitant of a broad range of central nervous system disorders. Nevertheless, its nosology, pathogenesis and therapy remain shrouded in confusion and controversy. As yet, there is little consensus regarding methods for detecting apathy, or distinguishing it from depression, or for assessing its severity. Many now regard the apathy syndrome as primarily reflecting a lack of motivation that compromises emotional, cognitive, and overt behavioral function. Even though under-recognized and under-diagnosed, apathy hardly appears uncommon: current epidemiologic studies suggest over 10 million Americans may be affected. Its reported frequency in various neurologic and psychiatric conditions varies widely, from less than 10 to over 80%, reflecting differences in population characteristics and assessment procedures. Often apathy has been associated with such neurodegenerative disorders as Alzheimer’s disease, Parkinson’s disease, and fronto-temporal dementia. But it also occurs in those with psychiatric disorders such as schizophrenia and major depression. Clinical, neuropathologic, and neuroimaging observations increasingly suggest that apathy reflects dysfunction of frontal-subcortical circuits, especially those linking the ventromedial prefrontal cortex to related regions in the basal ganglia. Therapeutically, numerous small studies suggest that psychostimulants, dopaminergics, and cholinesterase inhibitors may benefit those manifesting this syndrome. However, no adequately powered, randomized controlled trials have reported success and no medication have ever been approved for this disorder. The accelerating pace of current research nevertheless promises to improve our understanding of apathy and to better address the unmet medical needs of those suffering its consequences.
Similar content being viewed by others
References
Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FR (2005) The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry 20(6):523–530
Aalten P, van Valen E, de Vugt ME, Lousberg R, Jolles J, Verhey FR (2006) Awareness and behavioral problems in dementia patients: a prospective study. Int Psychogeriatr 18(1):3–17
Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL (2007) Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78:36–42
Acquas E, Carboni E, Leone P, Di Chiara G (1989) SCH 23390 blocks drug-conditioned place-preference and place-aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade? Psychopharmacology (Berl) 99(2):151–155
Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381
Alves GS, Alves CE, Lanna ME, Ericeira-Valente L, Sudo FK, Moreira D, Engelhardt E, Laks J (2009) Clinical characteristics in subcortical ischemic white matter disease. Arq Neuropsiquiatr 67(2A):173–178
Andersson S, Bergedalen AM (2002) Cognitive correlates of apathy in traumatic brain injury. Neuropsychiatry Neuropsychol Behav Neurol 15(3):184–191
Andersson S, Krogstad JM, Finset A (1999) Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity. Psychol Med 29(2):447–456
Angelelli P, Paolucci S, Bivona U, Piccardi L, Ciurli P, Cantagallo A, Antonucci G, Fasotti L, Di Santantonio A, Grasso MG, Pizzamiglio L (2004) Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. Acta Psychiatr Scand 110:55–63
Apostolova LG, Akopyan GG, Partiali N, Steiner CA, Dutton RA, Hayashi KM, Dinov ID, Toga AW, Cummings JL, Thompson PM (2007) Structural correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 24(2):91–97
Barbas NR (2006) Cognitive, affective, and psychiatric features of Parkinson’s disease. Clin Geriatr Med 22(4):773–796
Benoit M, Clairet S, Koulibaly PM et al (2004) Brain perfusion correlates of the apathy inventory dimensions of Alzheimer’s disease. Int J Geriatr Psychiatry 19:864–869
Bonelli RM, Cummings JL (2007) Frontal-subcortical circuitry and behavior. Dialogues Clin Neurosci 9(2):141–151
Borek LL, Chou KL, Friedman JH (2007) Management of the behavioral aspects of Parkinson’s disease. Expert Rev Neurother 7(6):711–725
Borroni B, Agosti C, Padovani A (2008) Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr 46(1):101–106
Borroni B, Alberici A, Agosti C, Cosseddu M, Padovani A (2009) Pattern of behavioral disturbances in corticobasal degeneration syndrome and progressive supranuclear palsy. Int Psychogeriatr 21(3):463–468
Bressan RA, Crippa JA (2005) The role of dopamine in reward and pleasure behaviour—review of data from preclinical research. Acta Psychiatr Scand 111(427 Suppl):14–21
Brodaty H, Sachdev PS, Withall A, Altendorf A, Valenzuela MJ, Lorentz L (2005) Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke—the Sydney Stroke Study. Psychol Med 35:1707–1716
Bruen PD, McGeown WJ, Shanks MF, Venneri A (2008) Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain 131(Pt 9):2455–2463
Cattelani R, Roberti R, Lombardi F (2008) Adverse effects of apathy and neurobehavioral deficits on the community integration of traumatic brain injury subjects. Eur J Phys Rehabil Med 44(3):245–251
Clarke DE, Reekum R, Simard M, Streiner DL, Freedman M, Conn D (2007) Apathy in dementia: an examination of the psychometric properties of the apathy evaluation scale. J Neuropsychiatry Clin Neurosci 19(1):57–64
Corcoran C, Wong ML, O’Keane V (2004) Bupropion in the management of apathy. J Psychopharmacol 18(1):133–135
Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP (2005) A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry 13:460–468
Crespi FN (2002) Daiichi seiyaku. Curr Opin Investig Drugs 3(5):788–793
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308–2314
Cummings JL, Mackell J, Kaufer D (2008) Behavioral effects of current Alzheimer’s disease treatments: a descriptive review. Alzheimers Dement 4(1):49–60
Czernecki V, Schipbach M, Yaici S, Levy R, Bardinet E, Yelnik J, Dubois B, Agid Y (2008) Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 23(7):964–969
Daiello LA (2007) Atypical antipsychotics for the treatment of dementia-related behaviors: an update. Med Health R I 90(6):191–194
David R, Koulibaly M, Benoit M, Garcia R, Caci H, Darcourt J, Robert P (2008) Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction. Clin Neurol Neurosurg 110(1):19–24
DeFord SM, Wilson MS, Gibson CJ, Baranova A, Hamm RJ (2001) Nefiracetam improves Morris water maze performance following traumatic brain injury in rats. Pharmacol Biochem Behav 69(3–4):611–616
Dellu F, Piazza PV, Mayo W, Le Moal M, Simon H (1996) Novelty-seeking in rats–biobehavioral characteristics and possible relationship with the sensation-seeking trait in man. Neuropsychobiology 34(3):136–145
Derouesne C (2004) Apathy: a useful but limited concept. Psychol Neuropsychiatr Vieil 2(1):19–28
DeVito EE, Salmond CH, Owler BK, Sahakian BJ, Pickard JD (2007) Caudate structural abnormalities in idiopathic normal pressure hydrocephalus. Acta Neurol Scand 116(5):328–332
Drapier D, Peron J, Leray E, Sauleau P, Biseul I, Drapier S, Le Jeune F, Travers D, Bourguignon A, Haegelen C, Millet B, Virin M (2008) Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson’s disease have separate neural substrates. Neuropsychologia 46(11):2796–2801
Drijgers RL, Aalten P, Winogrodzka A, Verhey FR, Leentjens AF (2009) Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review. Dement Geriatr Cogn Disord 28(1):13–22
Dujardin K, Sockeel P, Devos D, Delliaux M, Krystkowiak P, Destee A, Defebvre L (2007) Characteristics of apathy in Parkinson’s disease. Mov Disord 22(6):778–784
Dujardin K, Sockeel P, Delliaux M, DestÈe A, Defebvre L (2008) The Lille Apathy Rating Scale: validation of a caregiver-based version. Mov Disord 23(6):845–849
Faerden A, Nesvåg R, Barrett EA, Agartz I, Finset A, Friis S, Rossberg JI, Melle I (2008) Assessing apathy: the use of the Apathy Evaluation Scale in first episode psychosis. Eur Psychiatry 23(1):33–39
Faerden A, Vaskinn A, Finset A, Agartz I, Ann Barrett E, Friis S, Simonsen C, Andreassen OA, Melle I (2009) Apathy is associated with executive functioning in first episode psychosis. BMC Psychiatry 9:1
Farrar AM, Pereira M, Velasco F, Hockemeyer J, Muller CE, Salamone JD (2007) Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. Psychopharmacology (Berl) 191(3):579–586
Farrar AM, Font L, Pereira M, Mingote S, Bunce JG, Chrobak JJ, Salamone JD (2008) Forebrain circuitry involved in effort-related choice: injections of the GABAA agonist muscimol into ventral pallidum alter response allocation in food-seeking behavior. Neuroscience 152(2):321–330
Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI (2006) A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 67:1754–1759
Feil D, Razani J, Boone K, Lesser I (2003) Apathy and cognitive performance in older adults with depression. Int J Geriatr Psychiatry 18:479–485
Ferreri F, Agbokou C, Gauthier S (2006) Recognition and management of neuropsychiatric complications in Parkinson’s disease. CMAJ 175(12):1545–1552
Figved N, Klevan G, Myhr KM, Glad S, Nyland H, Larsen JP, Harboe E, Omdal R, Aarsland D (2005) Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatr Scand 112(6):463–468
Filali M, Lalonde R, Rivest S (2009) Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer’s disease. Genes Brain Behav 8(2):143–148
Freels S, Cohen D, Eisdorfer C, Paveza G, Gorelick P, Luchins DJ, Hirschman R, Ashford JW, Levy P, Semla T et al (1992) Functional status and clinical findings in patients with Alzheimer’s disease. J Gerontol 47(6):M177–M182
Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, Chabardes S, Foote K, Benabid AL, Pollak P (2004) Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry 75(6):834–839
Galvin JE, Malcom H, Johnson D, Morris JC (2007) Personality traits distinguishing dementia with Lewy bodies from Alzheimer disease. Neurology. 68:1895–1901
Gauthier S, Juby A, Rehel B, Schecter R (2007) EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer’s disease. Int J Clin Pract 61(6):886–895
Ghobrial MW, Ruby EB (2002) Coma and thyroid storm in apathetic thyrotoxicosis. South Med J 95(5):552–554
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, UPDRS Movement Disorder Society, Revision Task Force (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170
Gouliaev AH, Senning A (1994) Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 19(2):180–222
Haegelen C, Rouaud T, Darnault P, Morandi X (2009) The subthalamic nucleus is a key-structure of limbic basal ganglia functions. Med Hypotheses 72(4):421–426
Hamilton JM, Salmon DP, Corey-Bloom J, Gamst A, Paulsen JS, Jerkins S, Jacobson MW, Peavy G (2003) Behavioural abnormalities contribute to functional decline in Huntington’s disease. J Neurol Neurosurg Psychiatry 74:120–122
Hasegawa M, Nakayama S, Kinoshita H, Amano M, Yamada K, Hasegawa T, Nabeshima T (1996) Effects of the subacute administration of nefiracetam on abnormal behavior in aged rats. Behav Brain Res 78(2):93–100
Jin J, Watabe S, Yamamoto T (2002) Nefiracetam improves the impairment of local cerebral blood flow and glucose utilization after chronic focal cerebral ischemia in rats. Pharmacology 64:119–125
Joseph R (1999) Frontal lobe psychopathology: mania, depression, confabulation, catatonia, perseveration, obsessive compulsions, and schizophrenia. Psychiatry 62(2):138–172
Ketter TA, Post RM, Theodore WH (1999) Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53(5 Suppl 2):53–67
Kiang M, Christensen BK, Remington G, Kapur S (2003) Apathy in schizophrenia: clinical correlates and association with functional outcome. Schizophr Res 63:79–88
Kingma EM, van Duijn E, Timman R, van der Mast RC, Roos RA (2008) Behavioural problems in Huntington’s disease using the Problem Behaviours Assessment. Gen Hosp Psychiatry 30(2):155–161
Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D (2006) Dissociating apathy and depression in Parkinson disease. Neurology 67:33–38
Kirsch-Darrow L, Zahodne LB, Hass C, Mikos A, Okun MS, Fernandez HH, Bowers D (2009) How cautious should we be when assessing apathy with the Unified Parkinson’s Disease Rating Scale? Mov Disord 24(5):684–688
Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, GarcÌa-Sanchez C, Gironell A, Trapecio Group Study (2008) Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord 23(13):1889–1896
Lanctot KL, Moosa S, Herrmann N, Leibovitch FS, Rothenburg L, Cotter A, Black SE (2007) A SPECT Study of Apathy in Alzheimer’s Disease. Dement Geriatr Cogn Disord 24(1):65–72
Landes AM, Sperry SD, Strauss ME, Geldmacher DS (2001) Apathy in Alzheimer’s disease. J Am Geriatr Soc 49(12):1700
Landes AM, Sperry SD, Strauss ME (2005) Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 17:342–349
Lane-Brown A, Tate R (2009) Interventions for apathy after traumatic brain injury. Cochrane Database Syst Rev Apr 15(2):CD006341
Lauterbach EC (2004) The neuropsychiatry of Parkinson’s disease and related disorders. Psychiatr Clin North Am 27:801–825
Lavretsky H, Ballmaier M, Pham D, Toga A, Kumar A (2007) Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study. Am J Geriatr Psychiatry 15(5):386–394
Lechowski L, Benoit M, Chassagne P, Vedel I, Tortrat D, Teillet L, Vellas B (2009) Persistent apathy in Alzheimer’s disease as an independent factor of rapid functional decline: the REAL longitudinal cohort study. Int J Geriatr Psychiatry 24(4):341–346
Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG (2008) Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 23(14):2004–2014
Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ (2009) The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies. Clin Ther 31(1):89–98
Levy R, Czernecki V (2006) Apathy and the basal ganglia. J Neurol 253(Suppl 7):54–61
Levy R, Dubois B (2006) Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 16:916–928
Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I (1998) Apathy is not depression. J Neuropsychiatry Clin Neurosci 10(3):314–319
Lueken U, Seidl U, Völker L, Schweiger E, Kruse A, Schröder J (2007) Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents. Am J Geriatr Psychiatry 15(5):376–378
Luthman J, Lindqvist E, Kojima H, Shiotani T, Tanaka M, Tachizawa H, Olson L (1994) Effects of nefiracetam (DM-9384), a pyrrolidone derivative, on brain monoamine systems. Arch Int Pharmacodyn Ther 328(2):125–144
Malla AK, Norman RM, Williamson P (1993) Stability of positive and negative symptoms in schizophrenia. Can J Psychiatry 38(9):617–621
Malloy P, Grace J (2005) A review of rating scales for measuring behavior change due to frontal systems damage. Cogn Behav Neurol 18(1):18–27
Marangell LB, Johnson CR, Kertz B, Zboyan HA, Martinez JM (2002) Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry 63(5):391–395
Marin RS (1990) Differential diagnosis and classification of apathy. Am J Psychiatry 147(1):22–30
Marin RS (1996) Apathy: concept, syndrome, neural mechanisms, and treatment. Semin Clin Neuropsychiatry 1:304–314
Marin RS, Wilkosz PA (2005) Disorders of diminished motivation. J Head Trauma Rehabil 20:377–388
Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 38(2):143–162
Marin RS, Butters MA, Mulsant BH, Pollock BG, Reynolds CF (2003) Apathy and executive function in depressed elderly. J Geriatr Psychiatry Neurol 16:112–116
Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL (2006) Neuropathologic correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 21(3):144–147
Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL (2007) Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 64(7):1015–1020
Massimo L, Powers C, Moore P, Vesely L, Avants B, Gee J, Libon DJ, Grossman M (2009) Neuroanatomy of apathy and disinhibition in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 27(1):96–104
Mayo NE, Fellows LK, Scott SC, Cameron J, Wood-Dauphinee S (2009) A longitudinal view of apathy and its Impact after stroke. Stroke 40(10):3299–3307
McAllister TW (2000) Apathy. Semin Clin Neuropsychiatry 5:275–282
Mendez MF, Lauterbach EC, Sampson SM (2008) ANPA Committee on Research. An evidence-based review of the psychopathology of frontotemporal dementia: a report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 20(2):130–149
Migneco O, Benoit M, Koulibaly PM, Dygai I, Bertogliati C, Desvignes P, Robert PH, Malandain G, Bussiere F, Darcourt J (2001) Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer’s disease and non-demented patients. Neuroimage 13:896–902
Mizrahi R, Starkstein SE (2007) Epidemiology and management of apathy in patients with Alzheimer’s disease. Drugs Aging 24(7):547–554
Moriguchi S, Shioda N, Maejima H, Zhao X, Marszalec W, Yeh JZ, Fukunaga K, Narahashi T (2007) Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Mol Pharmacol 71(2):580–587
Ohtomo E (1994) Post stroke behavioral abnormalities treated with nefiracetam (DM9384). Igaku No Ayumi 170(9):777–816 Japanese
Okada K, Kobayashi S, Yamagata S, Takahashi K, Yamaguchi S (1997) Poststroke apathy and regional cerebral blood flow. Stroke 28(12):2437–2441
Padala PR, Burke WJ, Bhatia SC (2007) Modafinil therapy for apathy in an elderly patient. Ann Pharmacother 41(2):346–349
Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F (2010) Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 18(4):371–374
Pedersen KF, Larsen JP, Aarsland D (2008) Validation of the Unified Parkinson’s Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson’s disease. Parkinsonism Relat Disord 14(3):183–186
Pedersen KF, Larsen JP, Alves G, Aarsland D (2009) Prevalence and clinical correlates of apathy in Parkinson’s disease: a community-based study. Parkinsonism Relat Disord 15(4):295–299
Peters F, Perani D, Herholz K, Holthoff V, Beuthien-Baumann B, Sorbi S, Pupi A, Degueldre C, Lemaire C, Collette F, Salmon E (2006) Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. Dement Geriatr Cogn Disord 21(5–6):373–379
Pluck GC, Brown RG (2002) Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 73(6):636–642
Ramirez SM, Glover H, Ohlde C, Mercer R, Goodnick P, Hamlin C, Perez-Rivera MI (2001) Relationship of numbing to alexithymia, apathy, and depression. Psychol Rep 88(1):189–200
Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF (2009) The association between motor subtypes and psychopathology in Parkinson’s disease. Parkinsonism Relat Disord 15(5):379–382
Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314–1322
Reyes S, Viswanathan A, Godin O, Dufouil C, Benisty S, Hernandez K, Kurtz A, Jouvent E, O’Sullivan M, Czernecki V, Bousser MG, Dichgans M, Chabriat H (2009) Apathy: a major symptom in CADASIL. Neurology 72(10):905–910
Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, Caci H, Borg M, Brocker P, Bedoucha P (2002) The apathy inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry 17(12):1099–1105
Robert PH, Berr C, Volteau M, Bertogliati C, Benoit M, Sarazin M, Legrain S, Dubois B, the PréAL study (2006) Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. Clin Neurol Neurosurg 108:733–736
Robert P, Onyike CU, Leentjens AF, Dujardin K, Aalten P, Starkstein S, Verhey FR, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorca PM, Thibaut F, Gauthier S, Grossberg G, Vellas B, Byrne J (2009) Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 24(2):98–104
Robinson RG, Bloom FE (1977) Pharmacological treatment following experimental cerebral infarction: implications for understanding psychological symptoms of human stroke. Biol Psychiatry 12(5):669–680
Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S (2009) Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci 21:144–151
Rodda J, Morgan S, Walker Z (2009) Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer’s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21(5):813–824
Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, Ferrannini E, Tartaglione B, Defazio G, Rubini G, Livrea P (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 24(14):2097–2103
Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL (2005) Neuroanatomical correlates of behavioural disorders in dementia. Brain 128(11):2612–2625
Roth RM, Flashman LA, Saykin AJ, McAllister TW, Vidaver R (2004) Apathy in schizophrenia: reduced frontal lobe volume and neuropsychological deficits. Am J Psychiatry 161:157–159
Roth RM, Flashman LA, McAllister TW (2007) Apathy and its treatment. Curr Treat Options Neurol 9(5):363–370
Rushworth MF, Behrens TE, Rudebeck PH, Walton ME (2007) Contrasting roles for cingulate and orbitofrontal cortex in decisions and social behaviour. Trends Cogn Sci 11(4):168–176
Sakurai T, Kato T, Mori K, Takano E, Watabe S, Nabeshima T (1998) Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study. Neurosci Lett 246(2):69–72
Samus QM, Rosenblatt A, Steele C, Baker A, Harper M, Brandt J, Mayer L, Rabins PV, Lyketsos CG (2005) The association of neuropsychiatric symptoms and environment with quality of life in assisted living residents with dementia. Gerontologist 45 Spec No 1(1):19–26
Santa N, Sugimori H, Kusuda K, Yamashita Y, Ibayashi S, Iida M (2008) Apathy and functional recovery following first-ever stroke. Int J Rehabil Res 31(4):321–326
Siddique H, Hynan LS, Weiner MF (2009) Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer’s disease. J Clin Psychiatry 70(6):915–918
Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L (2006) The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 77(5):579–584
Spiegel DR, Kim J, Greene K, Conner C, Zamfir D (2009) Apathy due to cerebrovascular accidents successfully treated with methylphenidate: a case series. J Neuropsychiatry Clin Neurosci 21(2):216–219
Starkstein SE, Leentjens AF (2008) The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 79(10):1088–1092
Starkstein SE, Merello M (2007) The Unified Parkinson’s Disease Rating Scale: validation study of the mentation, behavior, and mood section. Mov Disord 22(15):2156–2161
Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4(2):134–139
Starkstein SE, Fedoroff JP, Price TR, Leiguarda R, Robinson RG (1993) Apathy following cerebrovascular lesions. Stroke 24(11):1625–1630
Starkstein SE, Petracca G, Chemerinski E, Kremer J (2001) Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry 158(6):872–877
Starkstein SE, Jorge R, Mizrahi R, Robinson RG (2006) A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 77(1):8–11
Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Power B (2009) The syndromal validity and nosological position of apathy in Parkinson’s disease. Mov Disord 24(8):1211–1216
Stout JC, Ready RE, Grace J, Malloy PF, Paulsen JS (2003) Factor analysis of the frontal systems behavior scale (FrSBe). Assessment 10(1):79–85
Svetel M, Potrebić A, Pekmezović T, Tomić A, Kresojević N, Jesić R, Dragasević N, Kostić VS (2009) Neuropsychiatric aspects of treated Wilson’s disease. Parkinsonism Relat Disord 15(10):772–775
Swanberg MM (2007) Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 21(2):164–166
Tagariello P, Girardi P, Amore M (2009) Depression and apathy in dementia: same syndrome or different constructs? A critical review. Arch Gerontol Geriatr 49(2):246–249
Takeo S, Fukatsu T, Miyake-Takagi K, Takagi N, Niimura M, Nagakura A, Ando T, Tanonaka K (2003a) Persistent effects of delayed treatment with nefiracetam on the water maze task in rats with sustained cerebral ischemia. J Pharmacol Exp Ther 304(2):513–523
Takeo S, Niimura M, Miyake-Takagi K, Nagakura A, Fukatsu T, Ando T, Takagi N, Tanonaka K, Hara J (2003b) A possible mechanism for improvement by a cognition-enhancer nefiracetam of spatial memory function and cAMP-mediated signal transduction system in sustained cerebral ischaemia in rats. Br J Pharmacol 138(4):642–654
Tekin S, Cummings JL (2002) Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 53(2):647–654
Thompson JC, Snowden JS, Craufurd D, Neary D (2002) Behavior in Huntington’s disease: dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci 14(1):37–43
Turro-Garriga O, Lopez-Pousa S, Vilalta-Franch J, Turon-Estrada A, Pericot-Nierga I, Lozano-Gallego M, Hernandez-Ferrandiz M, Soler-Cors O, Planas-Pujol X, Monserrat-Vila S, Garre-Olmo J (2009) A longitudinal study of apathy in patients with Alzheimer’s disease. Rev Neurol 48(1):7–13
van Duijn E, Kingma EM, van der Mast RC (2007) Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 19(4):441–448
van Reekum R, Stuss DT, Ostrander L (2005) Apathy: why care? J Neuropsychiatry Clin Neurosci 17:7–19
Velligan DI, Ritch JL, Sui D, DiCocco M, Huntzinger CD (2002) Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function. Psychiatry Res 113(3):227–236
Vicini Chilovi B, Conti M, Zanetti M, Mazzu I, Rozzini L, Padovani A (2009) Differential impact of apathy and depression in the development of dementia in mild cognitive impairment patients. Dement Geriatr Cogn Disord 27(4):390–398
von Cramon DY, Matthes-von Cramon G (1994) Recovery of higher-order cognitive deficits after brain hypoxia or frontomedial vascular lesions. Appl Neuropsychol 1(1–2):2–7
Watabe S, Taniguchi K, Kojima H (1994) Improvement of impaired brain monoamine metabolism by the cognition-enhancing agent nefiracetam after microsphere-induced cerebral embolism in rats. Arzneimittelforschung 44(2):195–198
Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB (2004) Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 52(5):784–788
Wicks P, Abrahams S, Papps B, Al-Chalabi A, Shaw CE, Leigh PN, Goldstein LH (2009) SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J Neurol 256(2):234–241
Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D (2007) Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann Gen Psychiatry 6:7
Yeager CA, Hyer L (2008) Apathy in dementia: relations with depression, functional competence, and quality of life. Psychol Rep 102(3):718–722
Yoshii M, Watabe S, Murashima YL, Nukada T, Shiotani T (2000) Cellular mechanism of action of cognitive enhancers: effects of nefiracetam on neuronal Ca2+ channels. Alzheimer Dis Assoc Disord 14(Suppl 1):S95–S102
Zahodne LB, Young S, Kirsch-Darrow L, Nisenzon A, Fernandez HH, Okun MS, Bowers D (2009) Examination of the Lille Apathy Rating Scale in Parkinson disease. Mov Disord 24(5):677–683
Zamboni G, Huey ED, Krueger F, Nichelli PF, Grafman J (2008) Apathy and disinhibition in frontotemporal dementia: insights into their neural correlates. Neurology 71(10):736–742
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chase, T.N. Apathy in Neuropsychiatric Disease: Diagnosis, Pathophysiology, and Treatment. Neurotox Res 19, 266–278 (2011). https://doi.org/10.1007/s12640-010-9196-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-010-9196-9